PAX5 and neuroblastoma: We can assume that the oncogenic effects of PAX5 may be associated with its negative regulation of expression of GRHL1 and GRHL3, since GRHL1 has been shown to be a tumor suppressor in neuroblastoma [58], whereas GRHL3 is a tumor suppressor in head and neck SCC [59].